3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Status
Terminated
4
Completed
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Plasma cell
4
Conditions
Multiple Myeloma
4
Renal Insufficiency
1
Immunoglobulin Light-chain Amyloidosis
1
Interventions
Dexamethasone
112
Bortezomib
61
Lenalidomide
49
Cyclophosphamide
49
Calcium Dobesilate
43
pomalidomide
32
Melphalan
31
fludarabine
25
Filgrastim
25
carfilzomib
22
fludarabine phosphate
21
daratumumab
20
Granulocyte Colony-Stimulating Factor
16
Whole-Body Irradiation
15
Antilymphocyte Serum
15
dexamethasone acetate
14
Mycophenolic Acid
14
Thalidomide
13
Tacrolimus
13
Cyclosporine
13
Busulfan
13
Peripheral Blood Stem Cell Transplantation
12
ixazomib
11
dexamethasone 21-phosphate
10
auricularum
10
pembrolizumab
9
Radiotherapy
9
Etoposide
9
belantamab mafodotin
8
Rituximab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Terminated
×
Multiple Myeloma
×
melflufen
×
Clear all
NCT03151811
2024-01-30
OCEAN
Oncopeptides AB
Phase 3
Terminated
495 enrolled
15 charts
NCT04649060
2023-06-08
LIGHTHOUSE
Oncopeptides AB
Phase 3
Terminated
54 enrolled
21 charts
NCT03639610
2023-03-10
BRIDGE
Oncopeptides AB
Phase 2
Terminated
35 enrolled
33 charts
NCT03481556
2022-12-19
ANCHOR
Oncopeptides AB
Phase 1/2
Terminated
56 enrolled
22 charts